Optimistic Buy Rating for BridgeBio Pharma’s BBP-812: Promising Phase 1/2 Results in Canavan Disease Therapy
Mizuho Securities analyst Salim Syed has maintained their bullish stance on BBIO stock, giving a Buy rating today. Salim Syed’s rating ...
BridgeBio Pharma’s BBP-812 Trial Shows Promise for Canavan Disease Amidst Focus on Acoramidis
Leerink Partners analyst Mani Foroohar has maintained their bullish stance on BBIO stock, giving a Buy rating today. Mani Foroohar’s ...
BriaCell reports survival data from Phase 2 study
BriaCell Therapeutics (TSX:BCT) has revealed new positive survival data in its Phase 2 metastatic breast cancer study ...
Whitecap Resources exceeds 2024 production guidance
Whitecap Resources (TSX:WCP) reports its operating and unaudited financial results for Q3 2024 ・The company exceeded its ...
TMCnet2d
BridgeBio Shares Positive Data from High Dose Cohort of Phase 1/2 CANaspire Study of Gene Therapy BBP-812 for Canavan Disease at ESGCT 2024
The disease is caused by an inherited mutation of the ASPA gene that codes for aspartoacylase, a protein that breaks down a compound called NAA. Deficiency of aspartoacylase activity results in ...
SeafoodNews5d
ASPA Reinforces That Commercial Wild-Caught Shrimp from Gulf of Mexico is Safe to Eat
It's "business as usual" for the commercial wild-caught shrimp industry in the Gulf of Mexico, according to the American Shrimp Processors Association (ASPA). The ASPA released a statement earlier ...
Seeking Alpha3d
MGXMF MGX Minerals Inc.
MGX Minerals Inc. engages in the acquisition, exploration, and development of mineral resource properties and industrial technologies. The company operates and invests in mineral property ...
Seeking Alpha1d
NVLPF Nova Leap Health Corp.
Nova Leap Health Corp., together with its subsidiaries, provides home and home health care services in the United States and Canada. Its services include dementia care, companionship, personal and ...